A new tablet of micronized 5-methoxypsoralen (5-MOP) and a commonly used tablet in therapy (Psoraderm 5) were compared in 12 healthy subjects. Each subject ingested 1.2 mg/kg body weight of each formulation on different days. Bioavailability and phototoxicity of 5-MOP were compared. The results showed that serum and suction blister concentrations were significantly higher and occurred earlier after the oral intake of the micronized preparation. A series of graduated UVA doses were administered, one dose each time the concentration serum peaked, in order to determine the minimum phototoxic dose for each formulation. The micronized preparation induced greater photosensitivity than the unmicronized one. The micronized 5-MOP tablet may thus allow lower doses of UVA to achieve therapeutic results in photochemotherapy and a shortened waiting period following ingestion of drug.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Treatment of psoriasis with a new micronized 5-methoxypsoralen tablet and UVA radiation.
Arch Dermatol Res
April 1994
Department of Functional Dermatology, University Hospital, Besançon, France.
Since 1974, phototherapy with psoralen and ultraviolet A (UVA) has been used successfully for the treatment of psoriasis. However, undesirable side effects, including phototoxicity, nausea, stomach pain and headaches, have led investigators to develop new psoralen compounds. 5-Methoxypsoralen (5-MOP) has thus been introduced as an alternative to 8-MOP because of its less pronounced side effects.
View Article and Find Full Text PDFA new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
Acta Derm Venereol
June 1992
Service de Dermatologie, Centre Hospitalier et Universitaire St Jacques, Besançon, France.
A new tablet of micronized 5-methoxypsoralen (5-MOP) and a commonly used tablet in therapy (Psoraderm 5) were compared in 12 healthy subjects. Each subject ingested 1.2 mg/kg body weight of each formulation on different days.
View Article and Find Full Text PDFPeak blistering point: influence on fluid levels of 5-MOP in human skin in vivo after systemic administration.
Arch Dermatol Res
November 1991
Department of Dermatology, Centre Hospitalier Universitaire Saint-Jacques, Besançon, France.
The concentration of 5-methoxypsoralen (5-MOP) in suction blister fluid (SBF) after oral intake was determined in relation to the peak blistering point. Interstitial fluid was obtained from nine healthy male volunteers by applying mild suction (300-350 mmHg) to the skin of the volar aspect of the forearm. Blisters were raised at three different times: 18 h prior to drug administration (group I); 2 h prior to drug administration (group II); and during drug ingestion (group III).
View Article and Find Full Text PDF5-Methoxypsoralen (5-MOP) (Psoraderm 5) tablets obtained from France and 5-MOP micronized in capsules (manufactured in our pharmacy department) were administered to seven psoriasis patients in a 1.2 mg/kg body weight dose schedule. Bioavailability and phototoxicity were compared.
View Article and Find Full Text PDFThe bioavailability of two galenic formulations of 5-methoxypsoralen (5-MOP) is described. A suspension in soft gelatine capsules was tested against a micronized powder in hard gelatine capsules on six volunteers, both in a dosage of 40 mg. The comparison of the AUC shows a significant better availability of the suspension (p less than or equal to 0.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!